Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with acute myeloid leukemia (AML) according to World Health Organization (WHO) guidelines
- People aged 18 years or older
- People whose AML is considered high-risk, meaning it falls into at least one of these categories: classified as high-risk by a standard European leukemia grading system (ELN 2022); developed from a pre-existing blood or bone marrow condition; or arose after previous chemotherapy or radiation treatment
- People who have not yet received treatment specifically for AML (apart from short-term medications used to lower very high white blood cell counts)
- People whose doctors expect them to survive at least 12 weeks
- People with a general health and functioning score of 3 or below on a standard scale used in cancer care (ECOG score)
- People whose kidneys are functioning at a sufficient level, measured by a standard test called creatinine clearance (confirm with trial site for exact threshold)
- People whose liver is functioning within acceptable limits, based on standard blood test results
- People who are willing and able to sign a consent form and follow the study requirements
Who may not be able to join:
- People diagnosed with a specific subtype of leukemia called acute promyelocytic leukemia
- People whose leukemia has spread to the central nervous system (brain and spinal cord)
- People with heart function problems rated above level 2 on a standard scale (confirm with trial site for exact definition)
- People living with HIV
- People with certain serious uncontrolled health conditions, including active uncontrolled infections (viral, bacterial, or fungal), hepatitis B or C requiring ongoing treatment, or another active cancer requiring treatment
- People who are unable to swallow oral medications or who have a digestive condition that would affect how the body absorbs medication
- People who have a known allergy to the study medications
- Women who are pregnant or breastfeeding
- People who are unable to understand or follow the study protocol
- People the trial doctor determines are not suitable for the study for other reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guopan Yu, Nanfang Hospital, Southern Medical University
Phone: +8615876559968
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite complete remission (CRc)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.